See the latest news and media coverage for Guardant Health. We track all announcements, press releases, and industry mentions in real time, all in one place.
Blood-based precision oncology company
guardanthealth.comLast updated
In short: Guardant Health secured multiple FDA approvals for its cancer diagnostics and expanded insurance coverage for the Shield screening test.
The liquid biopsy identifies ESR1 mutations in patients treated with AstraZeneca's camizestrant, enabling earlier therapy switching that improves progression-free survival by 56 percent.
Carelon Health Services will cover the FDA-approved Shield blood test starting November 15. This expansion brings total covered lives to approximately 90 million eligible U.S. patients.
Revenue grew 44% to $335.0 million; Screening up 250% to $52.9 million; FDA approvals for Guardant360 Liquid CDx and Shield workflow.
The largest US commercial insurer covers Shield for CRC screening, expanding access to 100 million lives.
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at Guardant Health...
Guardant360 CDx is the first FDA -approved liquid biopsy for comprehensive genomic profiling. It detects multiple genomic alterations across all solid tumors and is approved...
A Delaware federal judge has refused to throw out litigation accusing Tempus AI Inc. of infringing Guardant Health Inc. patents covering technology used to analyze...
Guardant Health stock has delivered very strong gains over the past three years, yet its valuation...
Track Guardant Health and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Guardant Health and other trending companies.